Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008

...quarter ended December 31, 2007 were $6.1 million, compared to $11.2 million for the comparable quarter of 2006, reflecting lower development costs of bremelanotide which were partially offset by an increase in general and administrative expenses due mainly to a $0.8 million litigation settlement agreement and rel...

Bremelanotide in Medical Technology

King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction

CRANBURY, N.J. and BRISTOL, Tenn., Aug. 30 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN ) and King Pharmaceuticals, Inc. (NYSE: KG ) announced today that they have delayed plans for the initiation of Phase 3 clinical trials with bremelanotide, a first in class melanocortin...

Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction

CRANBURY, N.J. and BRISTOL, Tenn., May 09, 2007 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and King Pharmaceuticals, Inc. today announced plans to present the results from two bremelanotide Phase 2b studies of men with erectile dysfunction (ED). The presenters are Jed Kaminetsky, MD, Cli...

Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide

CRANBURY, N.J., and BRISTOL, Tenn., May 22, 2007 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and King Pharmaceuticals, Inc. reported today that data from Study 16 and Study 17 of the Phase 2B clinical trial program evaluating bremelanotide in men with erectile dysfunction (ED) were presen...

Bremelanotide in Biological Technology

Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program

CRANBURY, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN ) today announced it has reacquired full rights to bremelanotide, a first in class melanocortin agonist drug candidate for the treatment of male erectile dysfunction (ED) and female sexual dysfunction (FS...

Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results

...ction, Palatin has discontinued development of bremelanotide for the treatment of male and female sexual dysfunction; -- Developing bremelanotide as a therapeutic drug for treatment of hemorrh...the reimbursement by King Pharmaceuticals, Inc. of bremelanotide development costs pursuant to the companies' colla...

Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007

...quarter ended September 30, 2007 were $9.6 million compared to $13.7 million for the comparable quarter of 2006, reflecting lower development costs of bremelanotide following the completion of certain Phase 2B clinical trials, which were partially offset by other research and development spending and higher stock-...

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007

...Phase 2A pilot study evaluating the effects of bremelanotide in post-menopausal women diagnosed with FSD in...of results from two Phase 2B trials evaluating bremelanotide for ED, with one trial limited to non-diabetic pat...ies was to characterize the efficacy and safety of bremelanotide in these two ED populations and to identify th...

Palatin Technologies Refutes Competitive Technologies Contention of Material Breach

...for further development of the compound. Palatin's bremelanotide compound was independently developed and patented by Palatin, and Palatin believes that bremelanotide is not covered by any of CTT's patents or patent rights. Whether bremelanotide is subject to the license agreement is an issue in...